Stocks Health care KRRO
NASDAQ · Health careKorro Bio, Inc. (KRRO)
Korro Bio, Inc. brought in $1.3M of revenue over the twelve months to September 30, 2026, down 82.5% from a year earlier. It posted a net loss of $106.1M. In fiscal 2025 capital spending exceeded operating cash flow by $79.1M. At September 30, 2026 it held $40.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Korro Bio, Inc.
- Net worth
- Korro Bio, Inc. has a market value (market cap) of $231.6M at the latest share price, and shareholders' equity of $88.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $6.4M (+181.5% year on year), with a net loss of $117.3M. Over the 12 months to September 30, 2026: revenue $1.3M, net loss $106.1M.
- Cash flow
- In fiscal 2025 operations used $78.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Korro Bio, Inc.'s next report is expected around March 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Korro Bio, Inc. does
Korro Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KRRO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $6.4M | -$117.3M | -$12.48 | -$79.1M |
| 2024 | $2.3M | -$83.6M | -$9.37 | -$78M |
| 2023 | $0 | -$81.2M | -$53.08 | -$75.1M |
| 2022 | $0 | -$58M | -$227.42 | -$58.8M |
| 2021 | $14.1M | -$84.7M | -$2.47 | -$79M |
| 2020 | $37M | -$26.5M | -$0.82 | -$51.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where KRRO ranks in Health care
Latest SEC filings
What Korro Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- October 22, 2026Other event 8-K
- October 5, 2026Other event 8-K
- August 19, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026
- August 6, 2026
- August 4, 2026Activist stake changed SCHEDULE 13D/A
Insider trades
What the people running Korro Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $884.8K and sold $1.2M worth of shares in the last 90 days. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 26, 2026 | Lynx1 Capital Management LP10% owner | Boughtindirect | 25,124 | $295.1K |
| October 23, 2026 | Lynx1 Capital Management LP10% owner | Boughtindirect | 2,510 | $30.4K |
| October 22, 2026 | Lynx1 Capital Management LP10% owner | Boughtindirect | 12,175 | $117.8K |
| October 22, 2026 | Lynx1 Capital Management LP10% owner | Boughtindirect | 40,000 | $441.5K |
| September 14, 2026 | Formela Jean FrancoisDirector | Soldpre-planned (10b5-1), indirect | 31,888 | $450.3K |
| September 14, 2026 | Formela Jean FrancoisDirector | Soldpre-planned (10b5-1), indirect | 6,602 | $93.2K |
| September 11, 2026 | Formela Jean FrancoisDirector | Soldpre-planned (10b5-1), indirect | 8,450 | $118.2K |
| September 11, 2026 | Formela Jean FrancoisDirector | Soldpre-planned (10b5-1), indirect | 1,750 | $24.5K |
Who owns KRRO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Atlas Venture Associates XI, L.P.13D, may seek influence with 4 related filers | 11.8% | November 13, 2023 |
| Lynx1 Capital Management LP13G, passive with 1 related filers | 10.7% | April 2, 2026 |
| Ali Behbahani13D, may seek influence with 11 related filers | 9.9% | March 12, 2026 |
| Venrock Healthcare Capital Partners III, L.P.13G, passive with 6 related filers | 9.9% | March 17, 2026 |
| Steven A. Cohen13G, passive with 5 related filers | 7.8% | November 14, 2024 |
| Balyasny Asset Management L.P.13G, passive with 4 related filers | 6.6% | August 14, 2026 |
| Nantahala Capital Management, LLC13G, passive with 2 related filers | 6.37% | February 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 107 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Lynx1 Capital Management LP | 1,538,296 | 0 |
| Nantahala Capital Management, LLC | 1,320,072 | +660,036 |
| NEA Management Company, LLC | 1,297,893 | 0 |
| Venrock Adviser, LLC | 1,009,500 | 0 |
| Atlas Venture Life Science Advisors, LLC | 962,884 | -174,265 |
| Balyasny Asset Management L.P. | 951,783 | -88,271 |
| BlackRock, Inc. | 817,621 | +357,615 |
| Affinity Asset Advisors, LLC | 706,904 | 0 |
| Adage Capital Partners GP, L.L.C. | 540,968 | +312,568 |
| ADAR1 Capital Management, LLC | 540,054 | 0 |
| Vanguard Capital Management LLC | 454,778 | +143,865 |
| Driehaus Capital Management LLC | 450,045 | 0 |
| TCG Crossover Management, LLC | 416,301 | 0 |
| Kalehua Capital Management LLC | 405,040 | +295,664 |
| Siren, L.L.C. | 347,718 | 0 |
| Aqr Capital Management LLC | 298,974 | +31,219 |
| Geode Capital Management, LLC | 296,870 | +123,227 |
| 72 Investment Holdings, LLC | 276,831 | 0 |
| State Street Corp | 232,587 | +92,246 |
| Vanguard Portfolio Management LLC | 223,551 | +74,992 |
Insiders
17 insiders reported holding 14,913,710 shares in total, about $234.6M at the last price.
| Holder | Shares |
|---|---|
| Lynx1 Capital Management LP10% owner | 1,624,7891,624,789 held indirectly |
| Sandell Scott D10% owner | 1,297,8931,297,893 held indirectly |
| Baskett Forest10% owner | 1,297,8931,297,893 held indirectly |
| Mathers Edward T10% owner | 1,297,8931,297,893 held indirectly |
| Walker Paul Edward10% owner | 1,297,8931,297,893 held indirectly |
| Florence Anthony A. Jr.10% owner | 1,297,8931,297,893 held indirectly |
| Behbahani AliDirector, 10% owner | 1,297,8931,297,893 held indirectly |
| Makhzoumi Mohamad10% owner | 1,297,8931,297,893 held indirectly |
| Chang Carmen10% owner | 1,297,8931,297,893 held indirectly |
| New Enterprise Associates 17, L.P.10% owner | 1,297,893 |
Questions about KRRO
What does Korro Bio, Inc. do?
Korro Bio, Inc. is a company in the Health care sector, listed on NASDAQ as KRRO. Its shares trade on NASDAQ under the ticker KRRO.
What is Korro Bio, Inc.'s net worth?
Korro Bio, Inc. has a market value (market cap) of $231.6M at the latest share price, and shareholders' equity of $88.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Korro Bio, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $106.1M on revenue of $1.3M.
How much revenue does Korro Bio, Inc. make?
Over the twelve months to September 30, 2026 Korro Bio, Inc. reported revenue of $1.3M. That is 82.5% less than a year earlier.
When did Korro Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Korro Bio, Inc.'s next earnings report?
Korro Bio, Inc.'s next report is expected around March 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare KRRO with
Follow KRRO
Get an email when Korro Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Korro Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.